RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Mar 10, 2014--Quintiles Transnational Holdings Inc. (“Quintiles”) (NYSE:Q) announced today the launch of a secondary public offering of its common stock. Certain shareholders of Quintiles (the “Selling Shareholders”) are offering for sale to the public 15 million shares of Quintiles’ common stock owned by them. The Selling Shareholders will grant to the underwriters of the secondary offering an option to purchase up to 2.25 million shares of additional common stock. Quintiles is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Shareholders in this offering.
Morgan Stanley, Barclays and J.P. Morgan are serving as joint book-running managers and as representatives of the underwriters for the offering. Citigroup, Goldman, Sachs & Co., Wells Fargo Securities, BofA Merrill Lynch and Deutsche Bank Securities are serving as book-running managers for the offering. Baird, William Blair and Jefferies are serving as lead co-managers, and Guggenheim Securities, Piper Jaffray, Raymond James, RBC Capital Markets and UBS Investment Bank are serving as co-managers for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. The offering will be made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, via telephone: +1 (866) 718-1649 or by email: email@example.com; Barclays Capital Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 via telephone: +1 (888) 603-5847, or by email: firstname.lastname@example.org; J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or via telephone: +1 (866) 803-9204.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 28,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements reflect, among other things, our current expectations and anticipated results of operations, all of which are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, market trends or industry results to differ materially from those expressed or implied by such forward-looking statements. Therefore, any statements contained herein that are not statements of historical fact may be forward-looking statements and should be evaluated as such. Without limiting the foregoing, the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “should,” “targets,” “will” and the negative thereof and similar words and expressions are intended to identify forward-looking statements. Actual results may differ materially from our expectations due to a number of factors, including that the proposed offering may be impacted by risks and uncertainties associated with market conditions, most of our contracts may be terminated on short notice, we may be unable to maintain large customer contracts or to enter into new contracts, we may under price our contracts or overrun our cost estimates, the historical indications of the relationship of our backlog to revenues may not be indicative of their future relationship, we operate in complex and changing regulatory and international environments, we may be unable to successfully identify, acquire and integrate existing businesses, and we have substantial indebtedness. For a further discussion of the risks relating to our business, see the “Risk Factors” section in our registration statement on Form S-1 relating to our secondary offering initially filed with the Securities and Exchange Commission (“SEC”) on February 21, 2014, as amended, and our other filings with the SEC. Unless legally required, we undertake no obligation to update any forward-looking statement after the date of this release, whether as a result of new information, future developments or otherwise.
Click here to subscribe to Mobile Alerts for Quintiles.
Phil Bridges, +1-919-998-1653 (office)
Karl Deonanan, +1-919-998-2789
KEYWORD: UNITED STATES NORTH AMERICA NORTH CAROLINA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
Copyright Business Wire 2014
PUB: 03/10/2014 06:30 AM/DISC: 03/10/2014 06:30 AM
Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.